Designing Shorter CRF Antagonists for Anxiety and Depression Treatment
Structure-activity studies on the CRF antagonist astressin identified the minimum peptide sequence needed for CRF receptor blockade, advancing toward smaller, more drug-like CRF antagonist anxiolytics.
Quick Facts
What This Study Found
SAR studies on astressin identified the minimal CRF antagonist sequence retaining biological activity at both CRF1 and CRF2 receptors, advancing design of smaller, more drug-like peptide antagonists for stress-related psychiatric disorders.
Key Numbers
How They Did This
in-vitro study on neuropeptides, anxiety-mood.
Why This Research Matters
Relevant for neuropeptides, anxiety-mood, peptide-design.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding SAR studies on astressin identified the minimal CRF antagonist sequence retaining biological activity at both CRF1 and CRF2 receptors, advancing desig
- Evidence Grade:
- preliminary evidence.
- Study Age:
- Published in 2004.
- Original Title:
- Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.
- Published In:
- Chembiochem : a European journal of chemical biology, 5(3), 340-8 (2004)
- Authors:
- Rijkers, Dirk T S(2), Kruijtzer, John A W, van Oostenbrugge, Marja, Ronken, Eric, den Hartog, Jack A J, Liskamp, Rob M J
- Database ID:
- RPEP-00966
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Designing Shorter CRF Antagonists for Anxiety and Depression Treatment
What was found?
Structure-activity studies on the CRF antagonist astressin identified the minimum peptide sequence needed for CRF receptor blockade, advancing toward smaller, more drug-like CRF antagonist anxiolytics.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00966APA
Rijkers, Dirk T S; Kruijtzer, John A W; van Oostenbrugge, Marja; Ronken, Eric; den Hartog, Jack A J; Liskamp, Rob M J. (2004). Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.. Chembiochem : a European journal of chemical biology, 5(3), 340-8.
MLA
Rijkers, Dirk T S, et al. "Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.." Chembiochem : a European journal of chemical biology, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Structure-activity studies on the corticotropin releasing fa..." RPEP-00966. Retrieved from https://rethinkpeptides.com/research/rijkers-2004-structureactivity-studies-on-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.